Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) saw strong trading volume on Wednesday . 2,746,555 shares changed hands during mid-day trading, an increase of 51% from the previous session’s volume of 1,819,601 shares.The stock last traded at $26.3360 and had previously closed at $25.68.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the stock. HC Wainwright reduced their target price on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a report on Thursday, April 30th. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Truist Financial raised Genmab A/S to a “strong-buy” rating in a report on Monday, April 27th. Finally, Jefferies Financial Group began coverage on Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $39.07.
Check Out Our Latest Analysis on Genmab A/S
Genmab A/S Price Performance
Genmab A/S (NASDAQ:GMAB – Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a net margin of 21.05% and a return on equity of 15.34%. Sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.19 EPS for the current fiscal year.
Institutional Trading of Genmab A/S
Several large investors have recently added to or reduced their stakes in GMAB. Federated Hermes Inc. purchased a new stake in shares of Genmab A/S during the third quarter valued at approximately $12,972,000. Oppenheimer Asset Management Inc. lifted its stake in shares of Genmab A/S by 24.1% in the third quarter. Oppenheimer Asset Management Inc. now owns 315,862 shares of the company’s stock worth $9,687,000 after acquiring an additional 61,311 shares in the last quarter. RFG Advisory LLC acquired a new position in shares of Genmab A/S in the third quarter worth about $1,298,000. Terra Nova Asset Management LLC acquired a new position in shares of Genmab A/S in the fourth quarter worth about $1,866,000. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Genmab A/S by 8.0% in the third quarter. Envestnet Asset Management Inc. now owns 809,939 shares of the company’s stock worth $24,841,000 after acquiring an additional 60,336 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.
Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.
Read More
- Five stocks we like better than Genmab A/S
- The Great AI Rotation: Cashing In on Data
- Mirum Pharma: A Rare Disease Growth Story to Watch
- The Great Cloud Divide: How AI Is Reshuffling the Software Deck
- Eagle Materials: A Dividend-Paying Brick & Mortar AI Play
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
